The Cadex Genomics mission and passion is to improve the lives of cancer patients. They have developed a novel, blood-based assays for patients with cancer. Over the past several years they have been working diligently to bring their first product to patients and the physicians who serve these patients. They are currently developing a new product called Alibrex, which is a blood-based assay that allows physicians to detect, in real-time, if the disease of their stage IV cancer patients is progressing.
Alibrex is currently at the clinical stage and will be available commercially in 2023. The team members have successful track records commercializing molecular diagnostics for oncology at companies including Genomic Health (now part of Exact Sciences), Castle Biosciences and Veracyte. Science and clinical team members are affiliated with the University of New Orleans, Tulane University and the University of California at San Francisco (UCSF). Independent board directors include the Chief Legal and Regulatory Officer for 23 and Me.
Clint McGill is addressing one of the biggest challenge in youth sports - building mental toughness. As a former high level baseball player himself,...
Eyetamins is a healthcare technology and life sciences company focused on therapeutics and consumer innovations in the $200B eye health and wellness space. They...
DenTriage is a comprehensive mobile and web-based platform that will provide a convenient way for patients to receive timely guidance and care for urgent...
